



PRESS RELEASE

Lund, 5 April 2016

Spago Nanomedical finalizes the active ingredient of SpagoPix

Spago Nanomedical has now completed the development of a nanomaterial with improved coating for the tumor selective contrast agent SpagoPix. The active ingredient of SpagoPix thus has the prerequisites for sufficient storage stability and is now ready for the biological verification preceding regulatory tests.

The SpagoPix contrast agent selectively accumulates in tumors and facilitates cancer diagnostics by magnetic resonance imaging (MRI). The completion of the final composition of the active ingredient of SpagoPix is a crucial step towards a product candidate and transition to regulatory development.

"We have now solved the issue of the nanoparticle coating which has been an obstacle to obtaining sufficient storage stability and have produced a material that meets the physical and chemical properties we want to see in the final version of SpagoPix", says Oskar Axelsson, CSO of Spago Nanomedical.

The nanomaterial, which now has the prerequisites to meet the stated specifications of a formal product candidate, will undergo in vivo tests to biologically verify the final formulation, i.e. the solution that is ultimately intended for administration to patients. This work has already been initiated and is expected to lead up to the designation of a final SpagoPix product candidate which will subsequently undergo regulatory preclinical tests prior to entering clinical trials in humans.

"The fact that we now have a material meeting our stability requirements is a major accomplishment by our co-workers and means that we can further strengthen the patent protection of both our lead projects, SpagoPix and Tumorad. In summary this is a considerable risk reduction in the development of the projects", says Mats Hansen, CEO of Spago Nanomedical.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company's development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch.

The aim of SpagoPix is to improve cancer diagnostics using magnetic resonance imaging (MRI) by facilitating early discovery of tumors and metastases. Early discovery improves the chances of efficient treatment and survival of cancer patients. Tumorad is a further development of the company's proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.

For further information, go to www.spagonanomedical.se.